
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37811654
CN-22-1578
10.2174/1570159X21666230920123401
Medicine, Neurology, Pharmacology, Neuroscience
Abusive use of Zolpidem as a Result of COVID-19 and Perspectives of Continuity of the Problem in the Post-Pandemic Period
de Lima Wesley Dawison 1
Douglas da Silva Michael 1
de Souza Costa Eurico 2
Pinheiro Francisco Irochima 2
de Azevedo Eduardo Pereira 2
Cobucci Ricardo Ney 23
de Paiva Cavalcanti José Rodolfo Lopes 45
Guzen Fausto Pierdoná 245*
1 Graduation in Medicine, Health Science Center, State University of Rio Grande do Norte (UERN), Mossoró- RN , Brazil;
2 Posgraduate Program of Biotechnology, Health School - Potiguar University (UnP), Natal-RN, Brazil;
3 Department of Tocogynecology, Medical School, Federal University of Rio Grande do Norte (UFRN), Natal-RN, Brazil;
4 Postgraduate Program in Physiological Sciences, Department of Biomedical Sciences, Faculty of Health Sciences, State University of Rio Grande do Norte (UERN), Mossoró- RN , Brazil;
5 Postgraduate Program in Health and Society, Department of Biomedical Sciences, Faculty of Health Sciences, State University of Rio Grande do Norte (UERN), Mossoró- RN , Brazil
* Address correspondence to this author at the Posgraduate Program of Biotechnology, Health School - Potiguar University (UnP), Natal-RN, Brazil; Postgraduate Program in Physiological Sciences, Department of Biomedical Sciences, Faculty of Health Sciences, State University of Rio Grande do Norte (UERN), Mossoró-RN, Brazil; and Postgraduate Program in Health and Society, Department of Biomedical Sciences, Faculty of Health Sciences, State University of Rio Grande do Norte (UERN), Mossoró-RN, Brazil; Brazil; Tel: +55-84-33152248; E-mail: faustoguzen@uern.br
20 9 2023
2024
22 10 15781582
25 2 2023
08 5 2023
10 5 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Zolpidem is a non-benzodiazepine hypnotic drug that works as a positive modulator of Gamma-Amino Butyric Acid-A (GABA-A) receptors, with high selectivity for α1 subunits. Given this selective binding, the drug has a strong hypnotic activity. Social isolation during the SARS-CoV-2 pandemic has contributed to increased rates of anxiety, depression, and insomnia. As a result, studies have pointed to a possible increase in the indiscriminate use of drugs with sedative effects, such as Zolpidem, during the pandemic. The aim of this work was to present prospective evidence that warns of the possibility of the abusive use of Zolpidem even after the pandemic. High rates of addiction to this drug have been reported around the world after the emergence of the coronavirus. Data from the National Survey on Drug Use and Health and from Medicaid support the continuing growth in prescription and indiscriminate use of Zolpidem during the pandemic and afterward. Therefore, there is enough evidence to support the indiscriminate use of this drug since the beginning of the pandemic. Rates of indiscriminate use of sedatives may continue to increase in the post-pandemic period, especially if strict control measures are not taken by health authorities.

Keywords

Zolpidem
COVID-19
pandemics
substance-related disorders
(GABA-A) receptors
drugs
==== Body
pmc1 INTRODUCTION

Zolpidem is a psychotropic drug defined as a non-benzodiazepine hypnotic, sedative agent (Z/NBZD), that works as a positive modulator of Gamma-Amino Butyric Acid-A (GABA-A) receptors, found primarily in the brain and spine [1]. In this sense, studies related to the pharmacodynamics of Zolpidem show that it has more affinity for GABA-A receptors in the brain, with high selectivity for α1 subunits [1, 2]. Given this selective binding, some authors claim that this drug has a marked hypnotic effect when compared to its myorelaxant and anticonvulsant activities, which makes it a promising agent for treating insomnia [1, 3].

This hypnotic activity considerably increases the duration of sleep and therefore, mitigates night awakening, which makes Zolpidem a more recommended drug even for older patients when compared to its peers in the benzodiazepine class. This seems to be due to the fact that this drug has very low mortality rates, as they lack the adverse effects of other drugs such as Diazepam and other anxiolytics [1, 4].

Despite being effective in the treatment of insomnia, Zolpidem has the potential to cause reactions and adverse effects that must be considered before use. It affects motor coordination, which increases the risk of falls and the incidence of fractures in the elderly population. Moreover, neuropsychological side effects have been reported, such as a significant reduction in attention and verbal memory, in addition to inducing a state of mental confusion, dizziness and drowsiness during the day [5-8].

Furthermore, studies have reported some cases of decreased awareness of surroundings, greater difficulty in processing thoughts, memory loss, sleepwalking and delirium [9, 10]. Another drug-related side effect described by some authors is the development of depression [11, 12]. The use of Zolpidem along with other central nervous system (CNS) depressant drugs substantially increases the likelihood of overdose [13]. It is imperative to emphasize that Zolpidem is an agent capable of generating euphoric and stimulating effects in its users [12, 14]. In this context, despite being a totally contradictory effect to its mechanism of action, studies have reported that the euphoric and alert effects may result from the use of high doses of this drug [12, 14-17].

As Zolpidem has the potential to cause addiction, a review was carried out on the evidence of growth in prescriptions as well as in the indiscriminate use of this drug after SARS-CoV-2 pandemic.

2 LITERATURE REVIEW

The authors searched for articles published in PUBMED, Science Direct, Google Scholar and Cochrane databases using the “mesh” terms COVID-19, Zolpidem, prescriptions, drug abuse and pandemic. The articles that presented data on the growth of abuse and prescription use Zolpidem since the beginning of the pandemic, as decreed by the world health organization, as well the manuscripts that reported cases of Zolpidem misuse, were all included in this search.

Milani et al. claim that the social isolation measures that had been taken to mitigate the spread of SARS-CoV-2 have contributed to increased rates of anxiety, depression and insomnia in the overall population. A cohort study conducted by these authors involving United States (US) population, revealed an increase in Z/NBZD and serotonergic drug prescriptions for both men and women along with an increase in benzodiazepine prescriptions for women at the start of the COVID-19 pandemic [18]. The 2020 National Survey on Drug Use and Health (NSDUH) examines the use and misuse of prescription sedatives that include Zolpidem products. Among people aged 12 or older in 2020, 2.2 percent (or 6.2 million people) misused sedatives [19].

A study analyzing the related European Medicines Agency (EMA) EudraVigilance (EV) databases confirmed the diversion potential and the possibility of abuse, misuse, dependence, and withdrawal issues related to all Z-drugs (zaleplon, zopiclone, and zolpidem) [20]. These results, as well as those of the NSDUH, are in line with the growth in rates of mental and sleep disorders observed in Brazil since the beginning of SARS-CoV-2 pandemic. Barros et al. concluded that there was an increase of approximately 43.5% in sleep-related problems in the Brazilian population during this period [21].

Saavedra et al. stated that a significant increase was clearly observed in the consumption of psychoactive drugs, particularly antidepressants, in the Brazilian capital, which is in accordance with the influence of the pandemic on the mental health of the general population [22]. However, in periods with greater restrictions triggered by the high mortality associated with the coronavirus infection, users of these drugs did not have the support of qualified health professionals to guide the correct and judicious use and therefore, some studies have shown an increase in the indiscriminate use of such agents, including Zolpidem [23, 24].

2.1 Abusive use Generating Dependence on Zolpidem

Authors have alerted, especially in the last two decades, about the drug dependence induced by the indiscriminate use of Zolpidem. Despite the fact that this drug was developed as an alternative to others anxiolytics, a series of case reports around the world have cautioned that there is indeed the possibility of development of drug dependence, especially in prolonged use [25, 15]. Orsolini et al. reported 8 cases of Zolpidem misuse and concluded that the drug should be prescribed with caution, as it can cause addiction [8]. Chiappini et al. also stated that the pandemic had a negative impact on the mental health of the world's population due to fear, social isolation and economic repercussions. Thus, the authors state that prescribers and pharmacists should be warned about possible requests to prescribe more drugs than needed to take home, which might be diverted and abused [26].

In England, high rates of drug addiction have been observed. Davies et al. reported that more than 250,000 English people have made indiscriminate use of Z drugs, including Zolpidem, beyond the time recommended by the British health authorities, which is 2 to 4 weeks of use [27]. In Brazil, data collected by the National Controlled Products Management System, which is responsible for overseeing the sales of psychotropics drugs in pharmacies and drugstores, revealed a marked increase in Zolpidem consumption during the pandemic [10, 22]. In Brazil, a substantial growth in search rates for Zolpidem on a drug price comparator platform was observed after the advent of the pandemic when compared to the pre-pandemic period [28]. Analysis of the legal commercialization of this drug has evidenced the emergence of an indiscriminate use of Zolpidem from the beginning of the pandemic until nowadays.

Furthermore, as advocated by Begum et al., prescriptions of Z/NBZD had a constant increase in countries with very high income, such as the United States and Sweden, even in the pre-pandemic period. However, the same authors claimed that restriction measures in Canada, Spain and South Korea, which includes charging for prescriptions as well as health insurance control, might have contributed to a reduction in the number of prescriptions of non-benzodiazepine hypnotics [29].

In Brazil, over the last few years, sales of Zolpidem registered by the National Health Surveillance Agency (ANVISA) increased by 645%, with 10 million boxes sold in 2022 alone [30]. This finding is in accordance with that found by Medcaid, a US public health program focused on serving the less financially favored sections of the population. Accordingly, there was an increase in the prescription of Zolpidem and a decrease in that of Lorazepam [30-34], which corroborates a predilection in the medical class for the former drug.

Another evidence that supports the indiscriminate use of this drug is the unprecedented finding of the presence of Zolpidem, among other sedatives/hypnotics, in wastewater in the United States and Mexico, as reported by Adhikari et al. (Fig. 1) [35].

The Nantes addict vigilance center, responsible for monitoring the use of Zolpidem in France, proposed two hypothesis that might justify the growing increase in its misuse: one relates to the drug’s hypnotic effects in relation to chronic sleep disorders and the other one relates to younger patients searching for the paradoxical amphetamine-like stimulant effects of zolpidem [15]. The World Health Organization (WHO) and the Food and Drug Administration (FDA) have provided alerts regarding the risks associated with zolpidem, especially drug dependence, thus suggesting dose reduction in some cases [36].

CONCLUSION

There is enough evidence to support the increased use of Zolpidem since the beginning of the SARS-CoV-2 pandemic. Rates of indiscriminate use of sedatives may continue to increase during the post-pandemic period if strict control measures are not taken by health authorities. Health professionals should be aware of the potential misuse of prescription drugs, especially Zolpidem. In addition, they must recognize the cases of drug abuse and prevent them whenever possible.

If the implementation of regulations that provide efficient control over the distribution and sale of Zolpidem fails, cases involving drug addiction and abusive use of this drug will gradually increase, motivated by factors such as the treatment of insomnia, the search for the sensation of euphoria arising from the consumption of high doses and the reduction in the efficiency of the hypnotic effect caused by long-term use. Therefore, it is concluded that the current indiscriminate use of Zolpidem since the beginning of the SARS-CoV-2 pandemic may become a serious public health problem in the near future. The implementation of successful measures, such as the regulatory framework for the prescription of Zolpidem adopted by France, may contribute to solving this problem, which has already been observed in many countries.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

GABA-A Gamma-Amino Butyric Acid-A

CNS Central Nervous System

EV EudraVigilance

FDA Food and Drug Administration

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) (1) Patient with insomnia (2) Acquisition of a medical prescription (3) Purchase of the medicine at the drugstore (4) Use of the medicine (5) Disposal of the medicine (6) Release into the sewage system (7) Detection in the exception of sewers (United States and Mexico) 8- Zolpidem structure. (Illustration: Francisco Irochima).
==== Refs
REFERENCES

1 Dang A. Garg A. Rataboli P.V. Role of zolpidem in the management of insomnia. CNS Neurosci. Ther. 2011 17 5 387 397 10.1111/j.1755-5949.2010.00158.x 20553305
2 Rowlett J.K. Woolverton W.L. Assessment of benzodiazepine receptor heterogeneity in vivo: Apparent pA 2 and pK B analyses from behavioral studies. Psychopharmacology (Berl.) 1996 128 1 1 16 10.1007/s002130050103 8944400
3 Salvà P. Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 1995 29 3 142 153 10.2165/00003088-199529030-00002 8521677
4 Woodward M. Hypnosedatives in the elderly. Mol. Diagn. Ther. 1999 11 263 279 10.2165/00023210-199911040-00003
5 Drake C.L. Durrence H. Cheng P. Roth T. Pillai V. Peterson E.L. Singh M. Tran K.M. Arousability and fall risk during forced awakenings from nocturnal sleep among healthy males following administration of Zolpidem 10 mg and Doxepin 6 mg: A randomized, placebo-controlled, four-way crossover trial. Sleep 2017 40 7 10.1093/sleep/zsx086 28575467
6 Poceta J.S. Zolpidem ingestion, automatisms, and sleep driving: A clinical and legal case series. J. Clin. Sleep Med. 2011 7 6 632 638 10.5664/jcsm.1468 22171202
7 Toner L.C. Tsambiras B.M. Catalano G. Catalano M.C. Cooper D.S. Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol. 2000 23 1 54 58 10.1097/00002826-200001000-00011 10682233
8 Orsolini L. Chiappini S. Grandinetti P. Bruschi A. Testa R. Provenzano A. Berardis D.D. Volpe U. ‘Z-trip’? A comprehensive overview and a case-series of zolpidem misuse. Clin. Psychopharmacol. Neurosci. 2021 19 2 367 387 10.9758/cpn.2021.19.2.367 33888666
9 Edinoff A.N. Wu N. Ghaffar Y.T. Prejean R. Gremillion R. Cogburn M. Chami A.A. Kaye A.M. Kaye A.D. Zolpidem: Efficacy and side effects for insomnia. Health Psychol. Res. 2021 9 1 24927 10.52965/001c.24927 34746488
10 Morais, Eduarda Valéria de Freitas. Descriptive analysis of the consumption of psychotropic drugs in Brazil: scenarios before and during the COVID-19 pandemic. 2022
11 Kripke D.F. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry 2007 7 1 42 10.1186/1471-244X-7-42 17711589
12 Lyu X. Hu Y. Zhao Y. Wang H. Du J. Wang J. Jiang H. Euphoric effect induced by zolpidem: A case study of magnetoencephalography. Gen. Psychiatr. 2022 35 1 e100729 10.1136/gpsych-2021-100729 35243205
13 Moore T.J. Mattison D.R. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern. Med. 2018 178 9 1275 1277 10.1001/jamainternmed.2018.3031 30014137
14 Sabe M. Kashef H. Gironi C. Sentissi O. Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Prog. Neuropsychopharmacol. Biol. Psychiatry 2019 94 109643 10.1016/j.pnpbp.2019.109643 31071363
15 Victorri-Vigneau C. Dailly E. Veyrac G. Jolliet P. Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br. J. Clin. Pharmacol. 2007 64 2 198 209 10.1111/j.1365-2125.2007.02861.x 17324242
16 Wang L.J. Ree S.C. Chu C.L. Juang Y.Y. Zolpidem dependence and withdrawal seizure--report of two cases. Psychiatr. Danub. 2011 23 1 76 78 21448102
17 Liappas I.A. Malitas P.N. Dimopoulos N.P. Gitsa O.E. Liappas A.I. Nikolaou C.H.K. Christodoulou G.N. A zolpidem and cocaine abuse case report. Int. J. Psychiatry Clin. Pract. 2002 6 4 217 219 10.1080/136515002761581036 24937116
18 Milani S.A. Raji M.A. Chen L. Kuo Y.F. Trends in the use of benzodiazepines, z-hypnotics, and serotonergic drugs among us women and men before and during the COVID-19 pandemic. JAMA Netw. Open 2021 4 10 e2131012 10.1001/jamanetworkopen.2021.31012 34694388
19 Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from: https://www.samhsa.gov/data/
20 Schifano F. Chiappini S. Corkery J.M. Guirguis A. An insight into Z-Drug abuse and dependence: An examination of reports to the european medicines agency database of suspected adverse drug reactions. Int. J. Neuropsychopharmacol. 2019 22 4 270 277 10.1093/ijnp/pyz007 30722037
21 Barros M.B.A. Lima M.G. Malta D.C. Szwarcwald C.L. Azevedo R.C.S. Romero D. Souza Júnior P.R.B. Azevedo L.O. Machado I.E. Damacena G.N. Gomes C.S. Werneck A.O. Silva D.R.P.D. Pina M.F. Gracie R. Report on sadness/] depression, nervousness/anxiety and sleep problems in the Brazilian adult population during the COVID-19 pandemic. Epidemiol. Serv. Saude 2020 29 4 e2020427 10.1590/s1679-49742020000400018 32844918
22 Escalante S.P.A. Galato D. de Souza Silva C.M. Rodrigues da Silva I.C. da Silva E.V. Dispensing of psychotropic drugs in the Brazilian capital city before and during the COVID-19 pandemic (2018–2020). Front. Pharmacol. 2022 13 1028233 10.3389/fphar.2022.1028233 36618914
23 Babicki M. Use of Alcohol, Cannabinoids, Psychostimulants, and Sedatives before and during the COVID-19 Pandemic among Students in 40 European Countries. Int. J. Environ. Res. Public Health 2022 19 22 14879 10.3390/ijerph192214879 36429598
24 Carrasco-Garrido P. Fernández-de-Las-Peñas C. Hernández-Barrera V. Palacios-Ceña D. Jiménez-Trujillo I. Gallardo-Pino C. Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors. Front. Med. (Lausanne) 2022 9 975930 10.3389/fmed.2022.975930 36160133
25 Heydari M. Isfeedvajani M.S. Zolpidem dependence, abuse and withdrawal: A case report. J. Res. Med. Sci. 2013 18 11 1006 1007 24520235
26 Chiappini S. Guirguis A. John A. Corkery J.M. Schifano F. COVID-19: The hidden impact on mental health and drug addiction. Front. Psychiatry 2020 11 767 10.3389/fpsyt.2020.00767 32848937
27 Davies J. Rae T.C. Montagu L. Long-term benzodiazepine and Z-drugs use in England: A survey of general practice. Br. J. Gen. Pract. 2017 67 662 e609 e613 10.3399/bjgp17X691865 28716996
28 Barreto Jr Epitacio de Paiva. O uso de psicotrópicos durante a pandemia da Covid-19: uma consequência do isolamento social. 2022. 45 fl. (Trabalho de Conclusão de Curso – Monografia). Curso de Bacharelado em Farmácia, Centro de Educação e Saúde, Universidade Federal de Campina Grande, Cuité – Paraíba – Brasil 2022
29 Begum M. Gonzalez-Chica D. Bernardo C. Woods A. Stocks N. Trends in the prescription of drugs used for insomnia: An open-cohort study in Australian general practice, 2011–2018. Br. J. Gen. Pract. 2021 71 712 e877 e886 10.3399/BJGP.2021.0054 33950853
30 Medicaid.gov. The official US government website for Medicare, 2022. Available from: https://www.medicaid.gov/
31 Chiaro G. Castelnovo A. Bianco G. Maffei P. Manconi M. Severe chronic abuse of zolpidem in refractory insomnia. J. Clin. Sleep Med. 2018 14 7 1257 1259 10.5664/jcsm.7240 29991431
32 Richter D. Riedel-Heller S. Zürcher S.J. Mental health problems in the general population during and after the first lockdown phase due to the SARS-CoV-2 pandemic: Rapid review of multi-wave studies. Epidemiol. Psychiatr. Sci. 2021 30 e27 10.1017/S2045796021000160 33685551
33 Melo J.R.R. Duarte E.C. Moraes M.V. Fleck K. Arrais P.S.D. Self-medication and indiscriminate use of medicines during the COVID-19 pandemic. Cad. Saude Publica 2021 37 4 e00053221 10.1590/0102-311x00053221 33852694
34 Westermeyer J. Carr T.M. Zolpidem-associated consequences. J. Nerv. Ment. Dis. 2020 208 1 28 32 10.1097/NMD.0000000000001074 31834190
35 Adhikari S. Kumar R. Driver E.M. Bowes D.A. Ng K.T. Sosa-Hernandez J.E. Oyervides-Muñoz M.A. Melchor-Martínez E.M. Martínez-Ruiz M. Coronado-Apodaca K.G. Smith T. Bhatnagar A. Piper B.J. McCall K.L. Parra-Saldivar R. Barron L.P. Halden R.U. Occurrence of Z-drugs, benzodiazepines, and ketamine in wastewater in the United States and Mexico during the COVID-19 pandemic. Sci. Total Environ. 2023 857 Pt 2 159351 10.1016/j.scitotenv.2022.159351 36243065
36 Food and Drug Administration FDA requires lower dosing of zolpidem. Med. Lett. Drugs Ther. 2013 55 1408 5 23348358
